Miller, David M <br/><br/>
Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.  [electronic resource] 

 -  Seminars in cutaneous medicine and surgery  Jun 2014 
 - 60-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1085-5629 
<br/><br/><label>Standard No.: </label>10.12788/j.sder.0081  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Immunotherapy<br/>Interferon-alpha--therapeutic use<br/>Interleukin-2--therapeutic use<br/>Melanoma--genetics<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Molecular Targeted Therapy<br/>Mutation<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-kit--genetics<br/>Skin Neoplasms--genetics